ArticleGynecologic oncology reports2026
Apparent diffusion coefficient values on MRI as biomarkers for pre operative prediction of prognostic factors in endometrial cancer.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Magnetic resonance imaging (MRI) is essential for preoperative assessment of endometrial carcinoma. Diffusion-weighted imaging (DWI)-derived apparent diffusion coefficient (ADC) values are being explored as quantitative, non-invasive biomarkers of tumor biology and aggressiveness. This study assessed the performance and interobserver reproducibility of ADC measurements for predicting prognostic factors. Methods: This study was conducted from June 2023 to June 2025 and included histologically confirmed endometrial carcinoma patients who underwent preoperative pelvic MRI. Patients with 3 T MRI outside the institute or unfit for primary surgery were excluded. Two radiologists independently measured focused-region and whole-lesion ADC values. Interobserver agreement was assessed using paired Results: Fifty-one patients were included, with endometrioid adenocarcinoma being the predominant histological subtype (92.2%). The mean ADC was 747.13 × 10 Conclusion: Focused ROI-based ADC assessment is practical, reproducible, contrast-free, and may improve risk stratification, surgical planning, and individualized management, especially where molecular testing is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.